Merck Discontinues Development of Osteoporosis Drug

Merck said it would discontinue developing the osteoporosis drug odanacatib and not seek regulatory approval for the treatment because it carries a higher risk of stroke.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news